STOCK
MLTX MOONLAKE IMMUNOTHERAPEUTICS
Held by 10 of 73 curated managers · 10 total holders in our 13F universe.
FUNDAMENTALS
Market Cap
$1.6B
P/E (Trailing)
—
P/E (Forward)
-5.55
PEG Ratio
—
Price/Book
5.31
Profit Margin
0.0%
Gross Margin
0.0%
Revenue Growth YoY
—
Earnings Growth YoY
—
Dividend Yield
0.0%
52-Week Range
$5.95 – $62.75
Fundamentals: Yahoo Finance · cached · Jul 29, 2026
SMART MONEY HOLDERS · from our curated set
Top managers holding MLTX
-
ADAR1 Capital Management, LLC Biotech picker with seventy-four percent alpha.0.5%
-
Two Sigma Investments, LP Quantitative arbitrage. Zero alpha. Known entity.0.0%
-
Citadel Advisors LLC Citadel — systematic quantitative dominance.0.0%
-
WINTON GROUP Ltd Berkshire proxy with modest alpha generation.0.0%
-
Renaissance Technologies LLC Quant. Different beast — opt in or out.0.0%
-
Tudor Investment Corp. Et Al Broad market tracker with modest leverage.0.0%
-
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Mega-cap tech concentration. Outsized alpha generation.0.0%
-
Citigroup Inc. Tech mega-cap concentration. Outperformance through concentration.0.0%
-
Vanguard Group Inc. Passive indexer with modest active tilts.0.0%
-
State Street Corp. Index tracker with mega-cap tech tilt.0.0%
EDITORIAL BRIEF
The editorial brief for MLTX is being prepared. Stock briefs roll out across Q3 starting with the most-held names.
INSIDER TRADES · recent
- Bvf Partners L P/Il Mar 31, 2026 SELL $32.44M
- Bvf Partners L P/Il Mar 31, 2026 SELL $26.35M
- Chen Bihua Sep 29, 2025 SELL $25.70M
- Chen Bihua Sep 29, 2025 SELL $18.51M
- Bvf Partners L P/Il Mar 31, 2026 SELL $4.17M
CONGRESS TRADES · recent
No STOCK Act trades on file for MLTX.